Transfüzyon Acillerine Yaklaşım

Authors

Yunus Tekin
https://orcid.org/0000-0002-1494-178X
Hüseyin Derya Dinçyürek

Synopsis

This section examines blood transfusion practices frequently used in clinical settings, the properties of blood products (whole blood, packed red blood cells, platelets, fresh frozen plasma, cryoprecipitate), and transfusion-related acute immunological and non-immunological reactions. It detailly addresses the clinical presentations and management of immunological complications—such as acute and delayed hemolytic reactions, febrile non-hemolytic reaction (FNHR), transfusion-related acute lung injury (TRALI), allergic reactions, transfusion-associated GVHD, and post-transfusion purpura—alongside non-immunological conditions including bacterial/viral transmissions and transfusion-associated circulatory overload (TACO). Adhering to restrictive hemoglobin thresholds for transfusion decisions (7 g/dL for hospitalized patients, 8 g/dL for patients with cardiac conditions), meticulously conducting pre-transfusion matching tests like cross-matching, and immediately stopping the transfusion while initiating prompt hydration, respiratory support, or specific medical interventions upon suspicion of a reaction are of critical, life-saving importance.

References

Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825-2836. doi:10.1016/S0140-6736(15)01313-6.

Hendrickson JE, Roubinian NH, Chowdhury D, et al. Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion. 2016;56(10):2587-2596. doi:10.1111/trf.13730

Raval JS, Griggs JR, Fleg A. Blood Product Transfusion in Adults: Indications, Adverse Reactions, and Modifications. Am Fam Physician. 2020;102(1):30-38.

Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic Transfusion Reactions. Longo DL, ed. N Engl J Med. 2019;381(2):150-162. doi:10.1056/NEJMra1802338

Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773-2781. doi:10.1182/blood-2018-02-785964

Roubinian N. TACO and TRALI: Biology, risk factors, and prevention strategies. Hematol (United States). 2018;2018(1):585-594. doi:10.1182/asheducation-2018.1.585

Hirayama F. Current understanding of allergic transfusion reactions : incidence , pathogenesis , laboratory tests , prevention and treatment. 2013;(December 2012):434-444. doi:10.1111/bjh.12150

Menis M, Forshee RA, Anderson SA, et al. Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012. Transfusion. 2015;55(2):284-295. doi:10.1111/trf.12782

Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133(17):1854-1864. doi:10.1182/blood-2018-11-833996

Andrzejewski C, Casey MA, Popovsky MA. How we view and approach transfusion-associated circulatory overload: Pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion. 2013;53(12):3037-3047. doi:10.1111/trf.12454

Published

May 20, 2021

License

License